Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study

British Journal of Cancer 115, 20 (28 June 2016). doi:10.1038/bjc.2016.119

Authors: F Mouriaux, V Servois, J J Parienti, T Lesimple, A Thyss, C Dutriaux, E M Neidhart-Berard, N Penel, C Delcambre, L Peyro Saint Paul, A D Pham, N Heutte, S Piperno-Neumann & F Joly

from Cancer via ola Kala on Inoreader http://ift.tt/29nd7pa
via IFTTT